Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) have changed the situation of tumor therapy in recent years. However, for security reasons, those special populations are often excluded from clinical trials, such as infected hepatitis B or hepatitis C patients. ICIs are systematically reviewed and me...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Huijing, Xue, Chongxiang, Zheng, Yumin, Zhang, Xu, Hu, Zixin, Lu, Xingyu, Yu, Yixuan, Li, Jia, Tan, Kexin, Cui, Huijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840556/
https://www.ncbi.nlm.nih.gov/pubmed/36647390
http://dx.doi.org/10.1155/2023/2525903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840556/
https://www.ncbi.nlm.nih.gov/pubmed/36647390
http://dx.doi.org/10.1155/2023/2525903

Ejemplares similares